申请人:Pfizer Inc.
公开号:US05783572A1
公开(公告)日:1998-07-21
Compounds of formula (I): ##STR1## and their pharmaceutically acceptable salts, wherein R.sup.1 and R.sub.2 are each independently Cl, Br, CH.sub.3, CH.sub.2 CH.sub.3 or CF.sub.3 ; R.sup.3 is H, CH.sub.3 or CH.sub.2 CH.sub.3 ; and X is a 5-membered heterocyclic group containing up to four nitrogen atoms, attached via a nitrogen atom, the said group being optionally substituted by C.sub.1 -C.sub.6 alkyl or (CH.sub.2).sub.n NR.sup.4 R.sup.5, wherein n is an integer from 1 to 5 and R.sup.4 and R.sup.5 are each independently H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl or C.sub.1 -C.sub.4 alkyl substituted by phenyl or pyridyl, or R.sup.4 and R.sup.5 are linked to form, together with the nitrogen atom to which attached, a pyrrolidine, piperidine, piperazine, N-(C.sub.1 -C.sub.4 alkyl) piperazine, morpholine or azepine group, or, when X is triazolyl, said group may optionally be benzofused, are NMDA antagonists of value in the treatment of acute neurodegenerative disorders, e.g. arising from stroke or traumatic head injury and in chronic neurological disorders, e.g. senile dementia and Alzheimer's disease.
公式(I)的化合物:##STR1##及其药用可接受的盐,其中R.sup.1和R.sub.2分别独立地为Cl、Br、CH.sub.3、CH.sub.2CH.sub.3或CF.sub.3;R.sup.3为H、CH.sub.3或CH.sub.2CH.sub.3;X为一个含有最多四个氮原子的5元杂环基,通过一个氮原子连接,该基可选择地被C.sub.1-C.sub.6烷基或(CH.sub.2).sub.nNR.sup.4R.sup.5取代,其中n为1至5的整数,R.sup.4和R.sup.5分别独立地为H、C.sub.1-C.sub.6烷基、C.sub.3-C.sub.6环烷基或由苯基或吡啶基取代的C.sub.1-C.sub.4烷基,或者R.sup.4和R.sup.5连接形成与连接的氮原子一起的吡咯烷、哌啶、哌嗪、N-(C.sub.1-C.sub.4烷基)哌嗪、吗啉或氮杂环基,或者当X为三唑基时,该基可选择地为苯并嵌合的,是一种在治疗急性神经退行性疾病中有价值的NMDA拮抗剂,例如由中风或创伤性头部损伤引起的疾病以及慢性神经疾病,例如老年性痴呆症和阿尔茨海默病。